Compounds > staurosporine
Page last updated: 2024-08-23

staurosporine and pd 184352

staurosporine has been researched along with pd 184352 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Dai, Y; Dent, P; Grant, S; McInistry, R; Singh, V; Tang, L; Wang, Z; Yu, C1
Dai, Y; Dent, P; Grant, S; Landowski, TH; Rosen, ST1
Dai, Y; Dawson, K; Dent, P; Gilfor, D; Grant, S; Hawkins, W; McKinstry, R; Mitchell, C; Ramakrishnan, V; Roberts, JD; Starkey, J; Yacoub, A1
Franklin, RA; Libra, M; McCubrey, JA; Stivala, F1
Dai, Y; Dent, P; Grant, S; Harada, H; Lu, J; Pei, XY; Tenorio, S1
Dai, Y; Dent, P; Grant, S; Tang, Y1

Other Studies

7 other study(ies) available for staurosporine and pd 184352

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
    Cancer research, 2001, Jul-01, Volume: 61, Issue:13

    Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Butadienes; Caspases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Flavonoids; HL-60 Cells; Humans; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Nitriles; Staurosporine; Tumor Cells, Cultured; U937 Cells

2001
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Alkaloids; Apoptosis; Benzamides; Bone Marrow Cells; CDC2 Protein Kinase; Cell Adhesion; Cell Cycle; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Free Radical Scavengers; Humans; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melphalan; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Syndecan-1; Syndecans; Tumor Cells, Cultured; Tumor Stem Cell Assay

2002
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
    Cancer biology & therapy, 2005, Volume: 4, Issue:11

    Topics: Apoptosis; Benzamides; Breast Neoplasms; Cell Death; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Staurosporine

2005
Two targets are better than one. Promising combination therapy to treat breast cancer.
    Cancer biology & therapy, 2005, Volume: 4, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Staurosporine

2005
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Blood, 2007, Sep-15, Volume: 110, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Benzamides; Blotting, Western; Drug Synergism; Enzyme Inhibitors; Humans; Immunoprecipitation; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Multiple Myeloma; Phosphorylation; Protein Conformation; Protein Kinase C; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Staurosporine; Subcellular Fractions

2007
Enhancing CHK1 inhibitor lethality in glioblastoma.
    Cancer biology & therapy, 2012, Volume: 13, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzamides; Benzimidazoles; Checkpoint Kinase 1; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase 4; Medulloblastoma; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Protein Kinases; Radiation-Sensitizing Agents; src-Family Kinases; Staurosporine; Tumor Cells, Cultured

2012